 Phase I, two-centre, open-label, randomized, gender-balanced, single-dose, laboratory blinded, two-period, two-sequence, crossover study in 2 groups of 20 healthy male and female subjects. The study consisted in 2 periods separated by a wash-out of at least 7 days between doses. To demonstrate the bioequivalence BE between two active product ingredient API sources current API source - marketed formulation MF versus new API source - to-be-marketed TBM of eslicarbazepine acetate ESL 